ASSOCIATE PROFESSOR NICHOLAS WILCKEN: BRIDGING RESEARCH AND CLINICAL CARE IN BREAST CANCER

About Associate Professor Nicholas Wilcken

Associate Professor Nicholas Wilcken was elected to the Breast Cancer Trials Board of Directors in July 2016 and is a member of the Scientific Advisory Committee.

He is the Director of Medical Oncology at the Crown Princess Mary Cancer Centre Westmead, and Associate Professor of Medicine at the University of Sydney.

His clinical interests are mainly in breast cancer and his research interests include systematic reviews and breast cancer clinical trials. He is currently the Co-ordinating Editor of the Cochrane Collaboration’s Breast Cancer Group. He has been an invited expert panel member for previous St Gallen Early Breast Cancer Consensus Conferences in Switzerland and is a member of the Steering Committee of the Early Breast Cancer Trialists’ Collaborative Group, based in Oxford, UK.

Biography

Associate Professor Nicholas Wilcken has an extensive background in medical education and oncology. He completed his medical studies at the University of New South Wales (UNSW) and underwent general medical training at Prince of Wales Hospital.

His specialised oncology training was conducted at Royal Prince Alfred Hospital, followed by a PhD at the Garvan Institute.

From 2011 to March 2017, he served as the Chair of the Breast Cancer Trials (BCT) Scientific Advisory Committee (SAC). Currently, he holds the position of Director of Medical Oncology at Westmead Hospital and is a Senior Staff Specialist at Nepean Hospital. Additionally, he serves as the Co-ordinating Editor for the Cochrane Collaboration Breast Cancer Group.

Qualifications and Professional Experience

• Bachelor of Medicine, University of NSW, 1984
• Bachelor of Surgery, University of NSW, 1984
• Fellow, Royal Australasian College of Physicians, 1992

STORIES FROM OUR RESEARCHERS

Our researchers work tirelessly to develop and conduct clinical trials because they see the benefits this research brings to their patients and all those affected by breast cancer.